Orange County Business Journal reported that Lineage Cell Therapeutics Inc. has officially completed a corporate acquisition involving NeuroAirmid Therapeutics Inc.

Through this specific business transaction, Lineage Cell Therapeutics Inc. acquired the worldwide rights for the HUNT1 neural cell therapy. NeuroAirmid Therapeutics Inc. operates as a specialized clinical-stage program that maintains a dedicated focus on a Huntington’s disease treatment.

The origins of the enterprise trace back directly to academic research directed by UCI professor Leslie Thompson. Because the scientific foundation rests entirely on research directed by UCI professor Leslie Thompson, the clinical-stage program carries strong academic roots tied directly to local research initiatives.

To test and evaluate the therapeutic approach in a practical environment, a Phase 1b/2a clinical trial is currently underway at UCI Health. This ongoing Phase 1b/2a clinical trial at UCI Health represents an active medical evaluation phase for the Huntington’s disease treatment within the local healthcare setting.

Regarding the financial agreements negotiated between the corporate entities, NeuroAirmid shareholders were paid $4.7 million in cash and shares at the formal closing of the transaction. This initial financial distribution of $4.7 million paid in cash and shares at closing provides the upfront remuneration for the stakeholders of NeuroAirmid Therapeutics Inc.

In addition to the initial $4.7 million paid in cash and shares at closing, the transaction structure establishes that NeuroAirmid shareholders could receive an additional $5 million payment next year. This potential additional payment next year offers further financial compensation as the business arrangement moves forward into its next operational phase.

Beyond the near-term financial terms, the acquisition agreement includes substantial long-term financial provisions for the parties involved. Specifically, there are up to $48 million available in development and regulatory milestones that can be achieved as the therapeutic program successfully progresses through required regulatory and developmental stages.

These up to $48 million available in development and regulatory milestones are specifically designed to incentivize the continued technical and clinical advancement of the clinical-stage program under the corporate stewardship of Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc. now maintains complete control over the worldwide rights for the HUNT1 neural cell therapy following the purchase of NeuroAirmid Therapeutics Inc. The ongoing Phase 1b/2a clinical trial at UCI Health continues to examine the Huntington’s disease treatment that originated from research directed by UCI professor Leslie Thompson, bringing together the academic discoveries of UCI professor Leslie Thompson and the corporate development capabilities of Lineage Cell Therapeutics Inc.